NASDAQ · PRE
Prenetics Global Limited
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
Loading market information…
NASDAQ · KRMD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
KORU Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
KORU Medical Systems, Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow KORU Medical Systems, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's primary offerings revolve around mechanical infusion solutions, notably their FREEDOM infusion systems. These comprehensive systems encompass components such as the FREEDOM60 and FreedomEdge syringe drivers, alongside specialized HIgH-Flo subcutaneous safety needle sets and precision flow rate tubing. Beyond their product range, KORU Medical also supplies educational content and training materials to healthcare professionals, patients, and patient advocates. The distribution of their products is managed through a combination of direct sales efforts, partnerships with medical device distributors, and online channels. Established in 1980, the firm's corporate headquarters are situated in Chester, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -$0.03-50.0% vs estimate | $9.64M+1.86% vs estimate |
|---|
| Q4 2024 | Mar 12, 2025 | -$0.030.0% vs estimate | $8.84M-0.28% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.03-21.07% vs estimate | $8.18M+0.64% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $6.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$18.98+$0.46 (+2.48%)
Prenetics Global Limited’s quoted price sits in the lower half of its reported 52-week range, 30.32% below the high.
$14.45+$0.13 (+0.91%)
InfuSystem Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.23% below the high.
$4.08-$0.02 (-0.49%)
OraSure Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.92% below the high.
$3.86-$0.07 (-1.78%)
TriSalus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.45% below the high.
$5.86+$0.08 (+1.38%)
Profound Medical Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.53% below the high.
$66.80-$2.04 (-2.96%)
Utah Medical Products, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.12% below the high.
$2.38+$0.12 (+5.31%)
Neuronetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.81% below the high.
$1.73+$0.02 (+1.17%)
MaxCyte, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.42% below the high.
